New drug combination key to very long-term leukemia remission in young patients
Researchers suggest that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions.
top of page
Brighter News features good news, compassionate news and inspirational news from around the world
bottom of page